ei1071
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 27, 2019 (NCT04238364)
Timeline
Indications
Mechanism of action
CSF1R inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06745583 | Phase 2 | Dec 31, 2024 | Elixiron Immunotherapeutics Inc. |
| NCT04238364 | Phase 1 | Dec 27, 2019 | Elixiron Immunotherapeutics Inc., Parexel |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Elixiron Immunotherapeutics Inc. | For profit | 2 | 2 | 2 | 2019 |
| Parexel | For profit | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1